1856 ET [Dow Jones]--Mondelez International says the rise of weight-loss drugs hasn't dented demand for its snacks, a trend it expects to continue. CEO Dirk Van de Put says the company's volume slowdown in North America is solely driven by economic anxieties and uncertainties, rather than any weight loss drug-related reduction in calorie intake. "I think even in 2026, and to be honest, when we even extrapolated for 10 years, we do not think that the effect will be significant," he says of the effect of GLP-1s on the company's business. (kelly.cloonan@wsj.com)
(END) Dow Jones Newswires
July 29, 2025 19:00 ET (23:00 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.